Investigation of tumour supressor protein p53 in renal cell carcinoma patients

Biomedical Papers

Volumn 158, Issue 1, 2014, Pages 44-49

  Hodorova, Ingrid ^a   Solar, Peter ^a   Mihalik, Jozef ^a   Vecanova, Janka ^a   Adamkov, Marian ^b   Rybarova, Silvia ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b Institute of Histology and Embryology Comenius University   (El Salvador)

Author keywords

Expression of p53; Immunohistochemistry; Renal cell carcinoma

Indexed keywords

PROTEIN P53;

CANCER GRADING; CHEMISTRY; FEMALE; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897461974     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.035     Document Type: Article

References (31)

1. Bast R, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E. Cancer medicine 2000; 5th ed. Hamilton, Ontario, Canada: B C Decker.
2. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-53.
3. Levine A.J, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351: 453-6.
4. Harris CC. Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Nat Cancer Inst 1996;88:1442-55.
5. Guimaraes DP, Hainaut P.TP53: a key gene in human cancer. Biochimie 2002;84:83-93.
6. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gurel G. P53 mutations and other prognostic factor of renal cell carcinoma. Urol Int 2001;66:78-83.
7. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4:215-23.
8. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'Ev A. Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci. 2002;973:374-83.
9. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2(10):731-7.
10. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18(53):7690-700.
11. Bot FJ, Godschalk JC., Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994;57:634-7.
12. Leonardi E, Luciani L, Reich A, Luciani LG, Dalla Palma P. Bivariate flow cytometric analysis of cytokeratin 19/dna content in renal cell carcinoma (rcc).Correlation with clinico-pathological features (t and g) and p53 expression. A prospective study on 84 cases. Wiley Cytometry Web Site-ISAC 2000 International Congress.Available from: http://www.wiley.com/legacy/products/subject/life/cytometry/isac2000/6349.htm.
13. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51(6):1057-61.
14. Sejima T and Miyagawa I. Expression of Bcl-2, p53 oncoprotein and Bax expression in renal cell carcinoma. Eur Urology 1999;35:242-8.
15. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S.Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59(4):615-20.
16. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G, Niehans GA. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994;5;(19):1470-5.
17. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6(5):1840-4.
18. Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, Guillé F, Ramée MP, Lobel B. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501-5.
19. Dippold WG, Jay G, DeLeo AB, Khoury G, Old LJ. P53 protein transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Sci USA 1981;78:1695-9.
20. Pillai G, Roberts H, Gatter K, Pezzela F.P53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology 2003;42:83-7.
21. Huang J, Soffer SZ, Kim ES, Yokoi A, Moore JT, McCrudden KW, Manley C, Middlesworth W, O'Toole K, Stolar C, Yamashiro DJ, Kandel JJ.P53 accumulation in favorable-histology Wilms tumour is associated with angiogenesis and clinically aggressive disease. Journal of Pediatric Surgery 2002;3:523-7.
22. Tomasino RM, Morello V, Tralongo V, Nagar C, Nuara R, Daniele E, Curti M, Orestano F. P53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994;86:227-33. Review.
23. Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996;16:3807-11.
24. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumour tissue. Urology 2004;63:651-5.
25. Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, Landberg G. P53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol 2001;35:15-20.
26. Punnet HH, Halligan GE, Zaeri N, Karmazin N. Translocation 10;17 in clear cell sarcoma of the kidney. A first report. Cancer Genet Cytogenet 1989;74:264-8.
27. Reiter RE, Anglard P, Liu S., Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 1993;53:3092-97.
28. Warburton HE, Brady M, Vlatkovič N, Linehan WM, Parsons K, Boyd MT. P53 regulation and function in renal cell carcinoma. Cancer Res 2005;65:6498-503.
29. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. P53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:951-58.
30. Thut CJ, Goodrich JA, Tjian R Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997;11(15):1974-86.
31. Kubbutat MH, Jones SN, Vousden KH Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299-303.